X46c96724.b37b.46c0.9cae.a4a1a5604bf0
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.530
- ANGIOGENESIS+0.510
- INFLAMMATORY_RESPONSE+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- IL6_JAK_STAT3_SIGNALING+0.420
- APICAL_SURFACE+0.410
- COAGULATION+0.380
- MYOGENESIS+0.380
- IL2_STAT5_SIGNALING+0.360
- ESTROGEN_RESPONSE_EARLY+0.330
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.440
- DNA_REPAIR-0.390
- MYC_TARGETS_V1-0.300
- PROTEIN_SECRETION-0.280
- E2F_TARGETS-0.250
- FATTY_ACID_METABOLISM-0.160
- MTORC1_SIGNALING-0.120
- GLYCOLYSIS-0.110
- PANCREAS_BETA_CELLS-0.100
- G2M_CHECKPOINT-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013602 | — | cohortMD2 | 0.924 |
| 2 | X25d3a106.8a9a.4285.9b02.1ba01b7a9ad2 | — | cohortMD2 | 0.918 |
| 3 | MNG721 | — | — | 0.917 |
| 4 | s_150324_1a | EPN | Posterior Fossa EPN | 0.908 |
| 5 | BS_G1Y281HX | Neuroblastoma | — | 0.899 |
| 6 | BS_0QYS36NR | EPN | EPN Tumor | 0.893 |
| 7 | TCGA-85-8049-01A-11R-2247-07 | — | cohortSQ1 | 0.892 |
| 8 | TCGA-BH-A0BO-01A-23R-A12D-07 | — | A | 0.886 |
| 9 | BS_0QYS36NR | Ependymoma NOS | — | 0.877 |
| 10 | SRR1516079 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.290 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |